Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: Experience of 154 patients with prognostic factor analysis

Japanese Journal of Clinical Oncology

Volumn 37, Issue 12, 2007, Pages 936-941

  Jo, Jae Cheol ^a   Lee, Jae Lyun ^a   Ryu, Min Hee ^a   Sym, Sun Jin ^a   Lee, Sung Sook ^a   Chang, Heung Moon ^a   Kim, Tae Won ^a   Lee, Jung Shin ^a   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Advanced gastric cancer; Docetaxel; Salvage chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOXIFLURIDINE; DOXORUBICIN; EPTAPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PLATINUM COMPLEX; UFT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; STOMACH ADENOCARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; VOMITING;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; STOMACH NEOPLASMS; TAXOIDS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 38749111139     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym123     Document Type: Article

References (29)

1. Shin HR, Jung KW, Won YJ, Park JG. 2002 annual report of the Korea Central Cancer Registry: Based on registered data from 139 hospitals. Cancer Res Treat 2004;36:103-14.
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
4. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
5. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 1999;80:269-72.
6. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil, versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
7. Kang Y-K, Kang W, Shin D, Chen D, Xiong J, Wang J, et al. Capecitabine/ cisplatin (XP) versus continuous infusion of 5-FU/cisplatin (FP) in patients (pts) with previously untreated advanced gastric cancer (AGC): Similar safety results from a phase III trial [abstract 77]. ASCO Gastrointestinal Cancers Symposium 2006.
8. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 2002;13:1893-8.
9. Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/ or metastatic gastric cancer. Ann Oncol 2004;15:1344-7.
10. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-12.
11. Jeung HC, Rha SY, Kim HK, Lim HY, Kim S, Kim SY, et al. Multi-institutional Phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. Oncologist 2007;12:543-54.
12. Lee J-L, Kang HJ, Kang Y-K, Ryu M-H, Chang HM, Kim T-W, et al. Phase I/ II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemother Pharmacol 2007 Jun 20; [Epub ahead of print]
13. Di Cosimo S, Ferretti G, Fazio N, Silvestris N, Carlini P, Alimonti A, et al. Docetaxel in advanced gastric cancer - review of the main clinical trials. Acta Oncol 2003;42:693-700.
14. Van Cutsem E. The treatment of advanced gastric cancer: New findings on the activity of the taxanes. Oncologist 2004;9:9-15.
15. Sulkes A, Smyth J, Sessa C, et al. Docetaxel (Taxotere™) in advanced gastric cancer: Results of a phase II clinical trial. Br J Cancer 1994;70:380-3.
16. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996;13:87-93.
17. 2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: A Phase II trial. Jpn J Clin Oncol 2002;32:248-54.
18. Lee J-L, Ryu M-H, Chang HM, Kim T-W, Yook JH, Oh ST, et al. Phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer failing fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol 2007 May 23; [Epub ahead of print].
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
20. Giuliani F, Gebbia V, De Vita F, Maielld E, Di Bisceglie M, Catalano G, Gebbia N, Colucci G. Docetaxel as salvage therapy in advanced gastric cancer: A phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res 2003;23:4219-22.
21. Taguchi T. A late phase II study of docetaxel in patients with gastric cancer [abstract]. Proceedings of the ASCO 1997;15:934.
22. Vanhoefer U. Phase II study of docetaxel as second-line chemotherapy in metastatic gastric cancer [abstract]. Proceedings of the ASCO 1999;18:1163.
23. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 1998;9:307-10.
24. Hartmann JT, Quietzsch D, Daikeler T, Kollmannsberger C, Mayer F, Kanz L, et al. Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anticancer Drugs 1999;10:729-33.
25. Chau I NA, Ross PJ. Multiviriate prognostic factor analysis and second-line treatment in locally advanced and metastatic oesophago-gastric cancer - pooled analysis of 1080 patients from three multicentre randomised controlled trials using individual patient data [abstract 5]. ASCO Gastrointestinal Cancers Symposium 2004.
26. Haller DG, Misset JL. Docetaxel in advanced gastric cancer. Anticancer Drugs 2002;13:451-60.
27. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol 2004;34:8-13.
28. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
29. Lee SS, Lee J-L, Ryu M-H, Chang HM, Kim TW, Kang H-J, et al. Combination chemotherapy with capecitabine (x) and cisplatin (p) as first line treatment in advanced gastric cancer: Experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol 2007;37:30-7.